What is the NOAEL for Enzacamene?
Enzacamene has 35 NOAEL studies in the database. The lowest reported value is 1 mg/kg bw/day via oral. Source: Regulatory source.
Also known as: Bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-3-[(4-methylphenyl)methylene]-, Eusolex 6300, Neo Heliopan MBC, 3-(p-Methylbenzylidene)camphor, 3-(p-Methylbenzylidene)-DL-camphor (+13 more)
CAS 36861-47-9
Enzacamene (CAS 36861-47-9) is a chemical substance. Key regulatory status: 4 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, AICIS, SCCS.
View cosmetic safety profile for Enzacamene (4-Methylbenzylidene Camphor) →
CAS, identifiers, formula, and alternate names for the matched substance record.
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| consumer_product | P&G | Proctor & Gamble |
| IFRA Transparency | IFRA | IFRA |
| Canada; consumer_product; Substances in Products - Canada (4/2014) | Government of Canada | CPCat |
| Canada; pharmaceutical | DrugBank | DrugBank |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 1 | - | - | oral | - | Regulatory source |
| 4 | - | - | - | - | Regulatory source |
| 25 | - | - | oral | rat | Regulatory source |
| 25 | mg/kg | - | dermal | rat | Regulatory source |
| 25 | mg/kg bw/day | - | - | - | Regulatory source |
| 25 | mg/kg bw/day | - | oral | - | Regulatory source |
| =30 | mg/kg bw/day | - | oral | rat | Regulatory source |
| 66 | mg/kg bw/day | - | dermal | human | Regulatory source |
| 100 | mg/kg/day | - | dermal | rat | Regulatory source |
| 100 | mg/kg bw/day | - | oral | - | Regulatory source |
| =400 | - | - | oral | rat | Regulatory source |
| 400 | mg/kg/day | - | dermal | rat | Regulatory source |
| 400 | mg/kg bw /day | - | oral | - | Regulatory source |
| 2000 | mg/kg bw/day | - | - | rat | Regulatory source |
| 8I3XWY40L9 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| =1 | - | NOAEL | oral | - | SCCS Opinion |
| =4 | - | NOAEL | - | - | SCCS Opinion |
| =10 | mg/kg bw/day | NOAEL | - | - | SCCS Opinion |
| =25 | - | NOAEL | oral | rat | SCCS Opinion |
| =25 | mg/kg/day | NOAEL | oral | rat | SCCS Opinion |
| =25 | mg/kg bw/day | NOAEL | dermal | - | SCCS Opinion |
| =25 | mg/kg | NOAEL | dermal | rat | SCCS Opinion |
| =25 | mg/kg bw/day | NOAEL | oral | rat | SCCS Opinion |
| =30 | mg/kg bw/day | NOAEL | oral | rat | SCCS Opinion |
| =30 | mg/kg bw/day | NOAEL | - | rat | SCCS Opinion |
| =50 | mg/kg/day | NOAEL | - | rat | SCCS Opinion |
| =50 | mg/kg bw/day | NOAEL | oral | - | SCCS Opinion |
| =66 | mg/kg bw/day | NOAEL | dermal | human | SCCS Opinion |
| =100 | mg/kg bw/day | NOAEL | - | - | SCCS Opinion |
| =100 | mg/kg/day | NOAEL | dermal | rat | SCCS Opinion |
| =100 | mg/kg bw/day | NOAEL | dermal | rat | SCCS Opinion |
| =400 | - | NOAEL | oral | rat | SCCS Opinion |
| =400 | mg/kg/day | NOAEL | dermal | rat | SCCS Opinion |
| =400 | mg/kg bw/day | NOAEL | oral | rat | SCCS Opinion |
| =400 | mg/kg bw /day | NOAEL | oral | - | SCCS Opinion |
Showing 35 of 35 studies
Australian industrial chemicals inventory status and applicable conditions.
EU Scientific Committee opinions tied to the matched substance.
| Opinion | Date | Conclusion | Max Conc. | Concerns |
|---|---|---|---|---|
| SCCP/1042/06 | 10 October 2006 | The SCCP is of the opinion that presently the safe use of a maximum concentration of 4% 4-MBC in sunscreens cannot be established. | 4% | Safe use of the proposed maximum concentration of 4% 4-MBC in sunscreens cannot presently be established. |
| SCCS/1640/21 | 29 April 2022 | The SCCS cannot conclude on the safety of 4-MBC, because the information provided is insufficient to fully evaluate potential genotoxicity. Moreover, there is sufficient evidence that 4-MBC may act as an endocrine disruptor and has effects on both the thyroid and estrogen systems. ... the use of 4-MBC at the maximum concentration of 4% in cosmetic ingredients would not be safe. ... It is not possible to derive a maximum concentration for safe use of 4-MBC, because a genotoxicity potential cannot be excluded. | 4% (proposed use as UV-filter; SCCS found NOT safe and could not derive any safe maximum concentration) | Information insufficient to fully evaluate potential genotoxicity (genotoxicity cannot be excluded); sufficient evidence that 4-MBC may act as an endocrine disruptor with effects on thyroid and estrogen systems; re-evaluation established a higher exposure level than the previous Opinion, lowering MoS so 4% would not be safe; no safe maximum concentration could be derived; environment not assessed (outside mandate). |
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
Enzacamene has 35 NOAEL studies in the database. The lowest reported value is 1 mg/kg bw/day via oral. Source: Regulatory source.
Enzacamene appears on 4 regulatory/inventory lists including consumer_product, IFRA Transparency, Canada; consumer_product; Substances in Products - Canada (4/2014), and 1 more. Source: EPA CPDat.
Yes, Enzacamene is also indexed as a cosmetic ingredient under the name Enzacamene (4-Methylbenzylidene Camphor). View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
Enzacamene also appears in cosmetics, pharmaceutical databases.